BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28212995)

  • 1. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Messaritakis I; Politaki E; Plataki M; Karavassilis V; Kentepozidis N; Koinis F; Samantas E; Georgoulias V; Kotsakis A
    Lung Cancer; 2017 Feb; 104():16-23. PubMed ID: 28212995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
    Messaritakis I; Stoltidis D; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Politaki E; Apostolaki S; Souglakos J; Georgoulias V
    Sci Rep; 2017 Mar; 7():45351. PubMed ID: 28349943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.
    Messaritakis I; Politaki E; Koinis F; Stoltidis D; Apostolaki S; Plataki M; Dermitzaki EK; Georgoulias V; Kotsakis A
    Sci Rep; 2018 Feb; 8(1):2238. PubMed ID: 29396560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
    Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
    PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
    Messaritakis I; Nikolaou M; Politaki E; Koinis F; Lagoudaki E; Koutsopoulos A; Georgoulia N; Georgoulias V; Kotsakis A
    Lung Cancer; 2018 Oct; 124():270-278. PubMed ID: 30268472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Koinis F; Agelaki S; Karavassilis V; Kentepozidis N; Samantas E; Peroukidis S; Katsaounis P; Hartabilas E; Varthalitis II; Messaritakis I; Fountzilas G; Georgoulias V; Kotsakis A
    Br J Cancer; 2017 Jun; 117(1):8-14. PubMed ID: 28510571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
    Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
    Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
    Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
    Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic and Predictive Value of Thyroid Transcription Factor-1, CD56, P40 and Other Clinical Characteristics in Small Cell Lung Cancer Patients].
    Wang X; Zhang Y; Hu M; Wang R; Liu L; Qian K; Li Y; Zhi X
    Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):522-527. PubMed ID: 28855032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients.
    Shi WL; Li J; Du YJ; Zhu WF; Wu Y; Hu YM; Chen YC
    Med Oncol; 2013 Dec; 30(4):755. PubMed ID: 24178178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
    Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
    PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients.
    Yoon SO; Kim YT; Jung KC; Jeon YK; Kim BH; Kim CW
    Lung Cancer; 2011 Feb; 71(2):209-16. PubMed ID: 20471712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
    Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
    J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
    Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
    J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.
    Hiltermann TJN; Pore MM; van den Berg A; Timens W; Boezen HM; Liesker JJW; Schouwink JH; Wijnands WJA; Kerner GSMA; Kruyt FAE; Tissing H; Tibbe AGJ; Terstappen LWMM; Groen HJM
    Ann Oncol; 2012 Nov; 23(11):2937-2942. PubMed ID: 22689177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
    Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.